Figure 1.

Schematic of the study protocol. The 141 patients treated with prophylaxis trimethoprim/sulfamethoxazole (TMP/SMX (+)) were excluded from the analysis, and the 561 patients who did not receive prophylaxis (TMP/SMX (-)) were analyzed to reveal risk factors for Pneumocystis pneumonia (PCP).

Katsuyama et al. Arthritis Research & Therapy 2014 16:R43   doi:10.1186/ar4472
Download authors' original image